ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
13.40
+0.35 (2.68%)
At close: Apr 3, 2025, 4:00 PM
13.01
-0.39 (-2.91%)
Pre-market: Apr 4, 2025, 9:10 AM EDT

Company Description

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions.

The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis.

It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.

ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals logo
Country United States
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 160
CEO Richard Lowenthal

Contact Details

Address:
11682 El Camino Real, Suite 120
San Diego, California 92130
United States
Phone 858 771 9307
Website ars-pharma.com

Stock Details

Ticker Symbol SPRY
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001671858
CUSIP Number 82835W108
ISIN Number US82835W1080
Employer ID 81-1489190
SIC Code 2834

Key Executives

Name Position
Richard Lowenthal M.B.A., M.S., MSMSEL Co-Founder, President, Chief Executive Officer and Director
Dr. Sarina Tanimoto M.B.A., M.D. Co-Founder and Chief Medical Officer
Alexander A. Fitzpatrick Esq. Chief Legal Officer and Secretary
Dr. Robert Bell Ph.D. Co-Founder and Chief Science Officer
Kathleen D. Scott CPA Chief Financial Officer
Brian T. Dorsey M.S. Chief Operations Officer
Daniel Relovsky Senior Vice President of Marketing
Harris Kaplan M.B.A. Executive Vice President of Commercial Strategy
Eric Karas Chief Commercial Officer
Justin Chakma Chief Business Officer and Secretary

Latest SEC Filings

Date Type Title
Mar 24, 2025 SCHEDULE 13D/A Filing
Mar 20, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 20, 2025 144 Filing
Mar 20, 2025 10-K Annual Report
Mar 20, 2025 8-K Current Report
Mar 5, 2025 144 Filing
Mar 5, 2025 8-K Current Report
Feb 3, 2025 144 Filing
Jan 31, 2025 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Jan 13, 2025 8-K Current Report